US20020040037A1 - Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol - Google Patents
Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol Download PDFInfo
- Publication number
- US20020040037A1 US20020040037A1 US09/931,431 US93143101A US2002040037A1 US 20020040037 A1 US20020040037 A1 US 20020040037A1 US 93143101 A US93143101 A US 93143101A US 2002040037 A1 US2002040037 A1 US 2002040037A1
- Authority
- US
- United States
- Prior art keywords
- compound
- hydroxy
- piperidin
- benzyl
- ethanesulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 title claims abstract description 9
- 239000000651 prodrug Substances 0.000 title description 24
- 229940002612 prodrug Drugs 0.000 title description 24
- 150000002148 esters Chemical class 0.000 title description 4
- ZIPCQEMYBOFDJP-UHFFFAOYSA-N 4-benzyl-1-[2-(2-hydroxyphenyl)sulfonylethyl]piperidin-3-ol Chemical compound C1CC(CC=2C=CC=CC=2)C(O)CN1CCS(=O)(=O)C1=CC=CC=C1O ZIPCQEMYBOFDJP-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 123
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 12
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Chemical group 0.000 claims abstract description 4
- 229910052717 sulfur Chemical group 0.000 claims abstract description 4
- 239000011593 sulfur Chemical group 0.000 claims abstract description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
- -1 4-methyl-piperazinyl Chemical group 0.000 claims description 11
- GJVDFRLJPJXWOC-YLJYHZDGSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] dihydrogen phosphate Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C1=CC=C(OP(O)(O)=O)C=C1 GJVDFRLJPJXWOC-YLJYHZDGSA-N 0.000 claims description 5
- JILXIKJEKZOLOE-DENIHFKCSA-N 4-[4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenoxy]-4-oxobutanoic acid Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C1=CC=C(OC(=O)CCC(O)=O)C=C1 JILXIKJEKZOLOE-DENIHFKCSA-N 0.000 claims description 4
- QMNKCPULZHXHJO-SHQCIBLASA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-(aminomethyl)benzoate Chemical compound C1=CC(CN)=CC=C1C(=O)OC1=CC=C(S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)C=C1 QMNKCPULZHXHJO-SHQCIBLASA-N 0.000 claims description 4
- DWIBODVLEBRCNQ-ZJSXRUAMSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-(3-aminopropanoylamino)propanoate Chemical compound C1=CC(OC(=O)CCNC(=O)CCN)=CC=C1S(=O)(=O)CCN1C[C@@H](O)[C@@H](CC=2C=CC=CC=2)CC1 DWIBODVLEBRCNQ-ZJSXRUAMSA-N 0.000 claims description 3
- ZSGMQPYYAUJBTJ-DLFZDVPBSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-(morpholin-4-ylmethyl)benzoate Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C(C=C1)=CC=C1OC(=O)C(C=1)=CC=CC=1CN1CCOCC1 ZSGMQPYYAUJBTJ-DLFZDVPBSA-N 0.000 claims description 3
- URPKAVROWQYPOZ-AKGWNBJDSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-[(4-methylpiperazin-1-yl)methyl]benzoate Chemical compound C1CN(C)CCN1CC1=CC=CC(C(=O)OC=2C=CC(=CC=2)S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)=C1 URPKAVROWQYPOZ-AKGWNBJDSA-N 0.000 claims description 3
- YMXOSPJJUJZVTR-QLWXXVCSSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-[(4-methylpiperazin-1-yl)methyl]benzoate Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)OC=2C=CC(=CC=2)S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)C=C1 YMXOSPJJUJZVTR-QLWXXVCSSA-N 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- ICLDVMBBZKNLHW-UFHPHHKVSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-(methylaminomethyl)benzoate Chemical compound CNCC1=CC=CC(C(=O)OC=2C=CC(=CC=2)S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)=C1 ICLDVMBBZKNLHW-UFHPHHKVSA-N 0.000 claims description 2
- XTWWONLTUVLHJR-LEAFIULHSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-(methylaminomethyl)benzoate Chemical compound C1=CC(CNC)=CC=C1C(=O)OC1=CC=C(S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)C=C1 XTWWONLTUVLHJR-LEAFIULHSA-N 0.000 claims description 2
- STGMSHRKRKTLJE-MXBOTTGLSA-N [4-[2-[(3S,4S)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 2-methyl-4-morpholin-4-ylbenzoate Chemical compound C([C@H]1CCN(C[C@H]1O)CCS(=O)(=O)C1=CC=C(C=C1)OC(=O)C1=CC=C(C=C1C)N1CCOCC1)C1=CC=CC=C1 STGMSHRKRKTLJE-MXBOTTGLSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 230000004770 neurodegeneration Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UDLDPIPQVZOCPK-YLJYHZDGSA-N (3s,4s)-4-benzyl-1-[2-(4-hydroxyphenyl)sulfonylethyl]piperidin-3-ol Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C1=CC=C(O)C=C1 UDLDPIPQVZOCPK-YLJYHZDGSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- MGKZKRJVQXEQPN-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1.CCC Chemical compound CC(=O)C1=CC=CC=C1.CCC MGKZKRJVQXEQPN-UHFFFAOYSA-N 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- 0 *OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)C(O)C2)C=C1 Chemical compound *OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)C(O)C2)C=C1 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 229940073584 methylene chloride Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- IJPXFZLLONEUFT-SHQCIBLASA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-(chloromethyl)benzoate Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C(C=C1)=CC=C1OC(=O)C1=CC=C(CCl)C=C1 IJPXFZLLONEUFT-SHQCIBLASA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- RIXHLQQGUMGPHT-QIKUIUABSA-N dibenzyl [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] phosphate Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C(C=C1)=CC=C1OP(=O)(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 RIXHLQQGUMGPHT-QIKUIUABSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- DWJDNKRPJKQLSX-YIXXDRMTSA-N [4-[2-[(3S,4S)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-(chloromethyl)benzoate Chemical compound C(C1=CC=CC=C1)[C@@H]1[C@@H](CN(CC1)CCS(=O)(=O)C1=CC=C(C=C1)OC(C1=CC(=CC=C1)CCl)=O)O DWJDNKRPJKQLSX-YIXXDRMTSA-N 0.000 description 3
- GCJOGIUMPXLEMJ-GRKNLSHJSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-(morpholin-4-ylmethyl)benzoate Chemical compound C([C@H]([C@H](CC1)CC=2C=CC=CC=2)O)N1CCS(=O)(=O)C(C=C1)=CC=C1OC(=O)C(C=C1)=CC=C1CN1CCOCC1 GCJOGIUMPXLEMJ-GRKNLSHJSA-N 0.000 description 3
- TZJMDJJXNZFPAO-POURPWNDSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1C(=O)OC1=CC=C(S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)C=C1 TZJMDJJXNZFPAO-POURPWNDSA-N 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- UAFBXOICOJEVCQ-UHFFFAOYSA-N 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(=O)NCCC(O)=O UAFBXOICOJEVCQ-UHFFFAOYSA-N 0.000 description 2
- HUOJYSVQAFOIHI-UHFFFAOYSA-N 3-[[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)N(C)CC1=CC=CC(C(O)=O)=C1 HUOJYSVQAFOIHI-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- XDRUIYOPZGBGDK-OGPPPPIKSA-N II.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 Chemical compound II.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 XDRUIYOPZGBGDK-OGPPPPIKSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UDOAINYRRKASBJ-SHQCIBLASA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoate Chemical compound C1=CC(OC(=O)CCNC(=O)CCNC(=O)OC(C)(C)C)=CC=C1S(=O)(=O)CCN1C[C@@H](O)[C@@H](CC=2C=CC=CC=2)CC1 UDOAINYRRKASBJ-SHQCIBLASA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YCAIYRWHKSJKEB-UHFFFAOYSA-N 3-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=CC(C(Cl)=O)=C1 YCAIYRWHKSJKEB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RCOVTJVRTZGSBP-UHFFFAOYSA-N 4-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=C(C(Cl)=O)C=C1 RCOVTJVRTZGSBP-UHFFFAOYSA-N 0.000 description 1
- LNKHBRDWRIIROP-UHFFFAOYSA-N 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1 LNKHBRDWRIIROP-UHFFFAOYSA-N 0.000 description 1
- DSFUNNWVQIDCEE-UHFFFAOYSA-N 4-[[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)N(C)CC1=CC=C(C(O)=O)C=C1 DSFUNNWVQIDCEE-UHFFFAOYSA-N 0.000 description 1
- 150000008626 4-imidazolidinones Chemical class 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- ACXUTGOYNSMNRB-JMRAGMMYSA-K C1COCCN1.CCC.CCC.CCN1CCN(C)CC1.CCN1CCOCC1.CN1CCNCC1.II.I[V]I.O=C(O)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1.[V]I Chemical compound C1COCCN1.CCC.CCC.CCN1CCN(C)CC1.CCN1CCOCC1.CN1CCNCC1.II.I[V]I.O=C(O)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1.[V]I ACXUTGOYNSMNRB-JMRAGMMYSA-K 0.000 description 1
- YGHPMARVWCKHMH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1.CCN(C)C.[V] Chemical compound CC(=O)C1=CC=CC=C1.CCN(C)C.[V] YGHPMARVWCKHMH-UHFFFAOYSA-N 0.000 description 1
- NTBCHALMYLHHCM-DDFMFRNISA-M CCC.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.[V]I Chemical compound CCC.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.[V]I NTBCHALMYLHHCM-DDFMFRNISA-M 0.000 description 1
- IZDPUDKHXHOLPE-APKGQRRKSA-N CCCOO.II.NCC(=O)NCC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=C(O)CC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=C1CCC(=O)O1.O=P(O)(O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 Chemical compound CCCOO.II.NCC(=O)NCC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=C(O)CC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=C1CCC(=O)O1.O=P(O)(O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 IZDPUDKHXHOLPE-APKGQRRKSA-N 0.000 description 1
- MIZQOSALFADHAO-DVQNPZQDSA-N CCN(C)C.II.O=C(O)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1.[H]N(C)CC.[V] Chemical compound CCN(C)C.II.O=C(O)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1.[H]N(C)CC.[V] MIZQOSALFADHAO-DVQNPZQDSA-N 0.000 description 1
- FBEZDTIVOSKBSC-VWTAZWEBSA-N CCN1CCN(C)CC1.CCN1CCOCC1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1 Chemical compound CCN1CCN(C)CC1.CCN1CCOCC1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1 FBEZDTIVOSKBSC-VWTAZWEBSA-N 0.000 description 1
- ALZJNRJUUUEFJH-MIPPOABVSA-N CCNC.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1 Chemical compound CCNC.O=C(OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1)C1=CC=CC=C1 ALZJNRJUUUEFJH-MIPPOABVSA-N 0.000 description 1
- ZHPPGKXDEXGNRX-UBFJJUSYSA-N Cl.C(C1=CC=CC=C1)[C@@H]1[C@@H](CN(CC1)CCS(=O)(=O)C1=CC=C(C=C1)OC(C1=CC(=CC=C1)CNC)=O)O Chemical compound Cl.C(C1=CC=CC=C1)[C@@H]1[C@@H](CN(CC1)CCS(=O)(=O)C1=CC=C(C=C1)OC(C1=CC(=CC=C1)CNC)=O)O ZHPPGKXDEXGNRX-UBFJJUSYSA-N 0.000 description 1
- CXEZLGAUKWAPGN-CUJAVGEGSA-N Cl.C(C1=CC=CC=C1)[C@@H]1[C@@H](CN(CC1)CCS(=O)(=O)C1=CC=C(C=C1)OC(C1=CC=C(C=C1)CNC)=O)O Chemical compound Cl.C(C1=CC=CC=C1)[C@@H]1[C@@H](CN(CC1)CCS(=O)(=O)C1=CC=C(C=C1)OC(C1=CC=C(C=C1)CNC)=O)O CXEZLGAUKWAPGN-CUJAVGEGSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XKNRRQVCMXQQMP-FDCKWBIYSA-N II.O=C1CCC(=O)O1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 Chemical compound II.O=C1CCC(=O)O1.O=S(=O)(CCN1CC[C@H](CC2=CC=CC=C2)[C@H](O)C1)C1=CC=C(O)C=C1 XKNRRQVCMXQQMP-FDCKWBIYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- KEFSNUGFPNCNIV-DENIHFKCSA-N NCC(=O)NCC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1 Chemical compound NCC(=O)NCC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1 KEFSNUGFPNCNIV-DENIHFKCSA-N 0.000 description 1
- HEOVZOVYJSCGCL-WIYYLYMNSA-N O=C(O)CC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1 Chemical compound O=C(O)CC(=O)OC1=CC=C(S(=O)(=O)CCN2CC[C@H](CC3=CC=CC=C3)[C@H](O)C2)C=C1 HEOVZOVYJSCGCL-WIYYLYMNSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- IJPXFZLLONEUFT-UHFFFAOYSA-N [4-[2-(4-benzyl-3-hydroxypiperidin-1-yl)ethylsulfonyl]phenyl] 4-(chloromethyl)benzoate Chemical compound C1CC(CC=2C=CC=CC=2)C(O)CN1CCS(=O)(=O)C(C=C1)=CC=C1OC(=O)C1=CC=C(CCl)C=C1 IJPXFZLLONEUFT-UHFFFAOYSA-N 0.000 description 1
- WGEZPBPKKHXFJS-DLFZDVPBSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 3-[[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]benzoate Chemical compound CC(C)(C)OC(=O)N(C)CC1=CC=CC(C(=O)OC=2C=CC(=CC=2)S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)=C1 WGEZPBPKKHXFJS-DLFZDVPBSA-N 0.000 description 1
- GROWFQXTTMGMJU-GRKNLSHJSA-N [4-[2-[(3s,4s)-4-benzyl-3-hydroxypiperidin-1-yl]ethylsulfonyl]phenyl] 4-[[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]benzoate Chemical compound C1=CC(CN(C)C(=O)OC(C)(C)C)=CC=C1C(=O)OC1=CC=C(S(=O)(=O)CCN2C[C@@H](O)[C@@H](CC=3C=CC=CC=3)CC2)C=C1 GROWFQXTTMGMJU-GRKNLSHJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Definitions
- the present invention is generally related to acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol, and more particularly to acid esters that enhance the solubility of the parent compound and are hydrolyzed under in vivo conditions thus serving as prodrugs for the parent compound.
- a prodrug is in most cases a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. It has been shown that a molecule with optimal structural configuration and physicochemical properties for eliciting the desired therapeutic response at its target site does not necessarily possess the best molecular form and properties for its delivery to its point of ultimate action. Usually, only a minor fraction of doses administered reaches the target area and since most agents interact with non-target sites as well, an inefficient delivery may result in undesirable side effects.
- Prodrugs are designed to overcome pharmaceutically and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug.
- the advantage of a prodrug lies in its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent drug, or it enhances absorption from the digestive tract, or it may enhance drug stability for long-term storage.
- NMDA N-methyl-D-aspartate
- Compounds of formula II have limited water solubility at physiological pH, not allowing bolus injections.
- a similar compound of formula II is generically described in WO 95/25721, wherein the formula does not contain a hydroxy group on the piperidine ring. These compounds are described to possess activities on the glutamat receptor or AMPA receptor for the treatment of diseases which are related to these receptors.
- the compound of formula II is a good NMDA receptor subtype specific blocker, neuroprotective in vivo and less active as blockers of the hERG potassium channels and thus is much less likely to have pro-arrhythmic activity in man.
- NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two subunit families show a distinct distribution in different brain areas. Heteromeric combinations of NR- 1 members with different NR-2 subunits result in NMDA receptors, displaying different pharmacological properties.
- NMDA receptor subtype specific blockers Possible therapeutic indications for NMDA receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, diseases such as schizophrenia, anxiety and depression and acute/chronic pain.
- acute forms of neurodegeneration caused, e.g., by stroke or brain trauma
- chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis)
- neurodegeneration associated with bacterial or viral infections diseases such as schizophrenia, anxiety and depression and acute/chronic pain.
- the present invention relates to a compound of the formula
- R 1 is —N(R 2 )(R 3 ) and R 2 /R 3 are hydrogen or lower alkyl, or is a five or six member aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from nitrogen, sulfur or oxygen, unsubstituted or substituted by lower alkyl,
- n 1,2,3 or 4;
- NMDA N-methyl-D-aspartate
- the compounds of the invention of formula I fulfill all requirements of a good prodrug. Specifically, it has been shown that compounds of the invention have up to 10-fold higher solubility over the parent compound at physiological pH. Additionally the compounds of the invention have an unexpected stability in solution at room temperature up to 48 h but also demonstrate a fast hydrolysis in plasma.
- the present invention is a novel compound of formula I, its use as a prodrug in the treatment or prophylaxis of diseases caused by overactivation of respective NMDA receptor subtypes, which include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and diseases such as schizophrenia, anxiety, depression and acute/chronic pain, the use of these compounds for manufacture of corresponding medicaments, processes for the manufacture of these novel compounds and medicaments, containing them.
- diseases such as schizophrenia, anxiety, depression and acute/chronic pain
- the most preferred indication in accordance with the present invention is the treatment or prevention of stroke.
- lower alkyl denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like.
- Preferred lower alkyl groups are groups with 1-4 carbon atoms.
- the term “five or six member aromatic or non-aromatic heterocyclic ring containing one or more hetero atoms selected from nitrogen, sulfur or oxygen, unsubstituted or substituted by lower alkyl” denotes, for example pyrrol-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl or morpholin-4-yl. Preferred are piperazin-1-yl or morpholin-4-yl. It is preferred that the heterocyclic rings contain one or two hetero atoms.
- physiological pH means a pH of around 7, preferably about 7.4.
- R 1 is as above. Especially preferred are compounds wherein R 1 is morpholinyl, 4-methyl-piperazinyl or —N(R 2 )(R 3 ) with R 2 and R 3 as above.
- R 1 is 4-methyl-piperazinyl. Examples of such compounds are:
- R 1 is —N(R 2 )(R 3 ) and R 2 /R 3 are hydrogen or lower alkyl. Examples of such compounds are:
- R is —C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 2 NH 2 , which is 3-(3-amino-propionylamino)-propionic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester.
- a compound of formula I may be prepared, for example, in accordance with reaction variant a) as follows:
- Process variant c) describes the process for preparation of a compound of formula I-3.
- the process is carried out by reacting the compound of formula II with a compound of formula IV, for example with 3-(3-tert-butoxycarbonylamino-propionylamino)-propionic acid, in the presence of DMAP (4-dimethylaminopyridine) and DAPEC (N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride) at a temperature of about 0° C.
- DMAP dimethylaminopyridine
- DAPEC N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride
- a compound of formula I-4 is obtained.
- the reaction is carried out by reaction of the compound of formula II with a compound of formula V, for example with 3-[(tert-butoxycarbonyl-methyl-amino)-methyl]benzoic acid, in the presence of DMAP (4-dimethylaminopyridine) and DAPEC (N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride) and subsequently with TFA (trifluoroacetic acid).
- DMAP dimethylaminopyridine
- DAPEC N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride
- TFA trifluoroacetic acid
- Process variant e) describes the preparation of compounds of formulas I-5 or I-6.
- a compound of formula VI for example 4-chloromethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester is treated with morpholine or 4-methyl-piperazin in a solvent, such as methylene chloride.
- the salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.
- the following schemes 1-3 describe the processes for preparation of the prodrugs of formula I in more detail.
- the starting compound of formula II (parent compound) may be prepared in accordance with schemes 4 to 6.
- the compounds, described in these schemes, are known compounds or may be prepared by known methods, for example in accordance with methods, described in WO 00/75109.
- hal is halogen, such as chloro or bromo.
- R 2 is hydrogen or lower alkyl.
- the compounds of formula I and their pharmaceutically acceptable addition salts may be used as prodrugs of the parent compounds of formula II, which possess valuable pharmacological properties.
- Plasma and blood samples from various species were spiked with equimolar amounts (26.7 ⁇ M) of the prodrug of the invention and parent drug in DMSO and incubated for different time intervals (up to 120 min) at 37° C.
- the reaction was stopped by protein precipitation with perchloric acid (0.5 M) followed by centrifugation (5 min. at 15'000 g). This procedure was found to be reliable enough at least when the drug analysis was performed immediately after the incubation.
- the concentrations of formed parent drug in the supernatant was determined by LC-MS:
- the parent compound together with its hexa- 13 C-labelled internal standard was enriched on a standard bore trapping column (Lichrospher100, RP18, 5 ⁇ m, 4 ⁇ 4 mm, Merck) and separated under isocratic conditions on a narrow-bore analytical column (Symmetry Shield, RP8, 3.5 ⁇ m, 2.1 ⁇ 50 mm, Waters) by a mixture of formic acid and methanol as mobile phase.
- the whole effluent (200 ⁇ l/min) of the analytical column was passed to the turbo ion spray interface without splitting.
- the compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
- the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
- the administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- the compounds of formula I and their pharmaceutically acceptable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
- Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
- Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
- Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
- Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
- the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
- reaction mixture was concentrated to 10 ml and was purified by chromatography over silica gel to give 100 mg (0.21 mmol, 7.4%) succinic acid mono- ⁇ (3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ⁇ ester as colorless oil.
- the title compound was prepared from 3-(3-tert-butoxycarbonyl-methyl-amino-methyl) benzoic acid and (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 93% yield as a colorless solid.
- the title compound was prepared from (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol and 3-(3-tert-butoxycarbonylamino-propionylamino)-propionic acid in 13% yield as a colorless solid.
- Tablets of the following composition are manufactured in the usual manner: mg/tablet Prodrug 5 Lactose 45 Corn starch 15 Microcrystalline cellulose 34 Magnesium stearate 1 Tablet weight 100
- Capsules of the following composition are manufactured: mg/capsule Prodrug 10 Lactose 155 Corn starch 30 Talc 5 Capsule fill weight 200
- the active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine.
- the mixture is returned to the mixer, the talc is added thereto and mixed thoroughly.
- the mixture is filled by machine into hard gelatine capsules.
- the suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository molds of suitable size, left to cool, the suppositories are then removed from the molds and packed individually in wax paper or metal foil.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention is generally related to acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol, and more particularly to acid esters that enhance the solubility of the parent compound and are hydrolyzed under in vivo conditions thus serving as prodrugs for the parent compound.
- A prodrug is in most cases a pharmacologically inactive derivative of a parent drug molecule that requires spontaneous or enzymatic transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. It has been shown that a molecule with optimal structural configuration and physicochemical properties for eliciting the desired therapeutic response at its target site does not necessarily possess the best molecular form and properties for its delivery to its point of ultimate action. Usually, only a minor fraction of doses administered reaches the target area and since most agents interact with non-target sites as well, an inefficient delivery may result in undesirable side effects. This fact of differences in transport and in situ effect characteristics for many drug molecules is the basic reason why bioreversible chemical derivatization of drugs, i.e., prodrug formation is a means by which a substantial improvement in the overall efficacy of drugs can often be achieved.
- Prodrugs are designed to overcome pharmaceutically and/or pharmacokinetically based problems associated with the parent drug molecule that would otherwise limit the clinical usefulness of the drug. The advantage of a prodrug lies in its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent drug, or it enhances absorption from the digestive tract, or it may enhance drug stability for long-term storage.
- In recent years several types of bioreversible derivatives have been exploited for utilization in designing prodrugs. Using esters as a prodrug type for drugs containing carboxyl or hydroxyl function is most popular. Further well-known are prodrug derivatives of peptides, 4-imidazolidinones and the like, described in Drugs of the Future, 1991, 16(5), 443-458 or N-oxides, described for example in U.S. Pat. No. 5,691,336.
-
- are known as NMDA (N-methyl-D-aspartate)-receptor-subtype selective blockers. Compounds of formula II have limited water solubility at physiological pH, not allowing bolus injections. A similar compound of formula II is generically described in WO 95/25721, wherein the formula does not contain a hydroxy group on the piperidine ring. These compounds are described to possess activities on the glutamat receptor or AMPA receptor for the treatment of diseases which are related to these receptors.
- Similar compounds are described in EP 824 098, in which the piperidine ring is substituted by a hydroxy group in 4-position. These compounds are described to possess activities on the NMDA receptor and are useful in the treatment of acute forms of neurodegeneration caused, for example, by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, ALS (amyotrophic lateral sclerosis), neurodegeneration associated with bacterial or viral infections and acute/chronic pain. Furthermore, it is known from WO 00/75109, that the compound of formula II is a good NMDA receptor subtype specific blocker, neuroprotective in vivo and less active as blockers of the hERG potassium channels and thus is much less likely to have pro-arrhythmic activity in man.
- Under pathological conditions of acute and chronic forms of neurodegeneration overactivation of NMDA receptors is a key event for triggering neuronal cell death. NMDA receptors are composed of members from two subunit families, namely NR-1 (8 different splice variants) and NR-2 (A to D) originating from different genes. Members from the two subunit families show a distinct distribution in different brain areas. Heteromeric combinations of NR- 1 members with different NR-2 subunits result in NMDA receptors, displaying different pharmacological properties. Possible therapeutic indications for NMDA receptor subtype specific blockers include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, diseases such as schizophrenia, anxiety and depression and acute/chronic pain.
-
- wherein
- R is
- a) —C(O)(CH2)nC(O)OH,
-
- wherein R1 is —N(R2)(R3) and R2/R3 are hydrogen or lower alkyl, or is a five or six member aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from nitrogen, sulfur or oxygen, unsubstituted or substituted by lower alkyl,
- c) —P(O)(OH)2, or is
- d) —C(O)(CH2)nNHC(O)(CH2)nN(R2)(R3); and
- n is 1,2,3 or 4;
- or a pharmaceutically acceptable acid addition salt thereof.
-
- which are NMDA (N-methyl-D-aspartate)-receptor-subtype selective blockers.
- It has surprisingly been shown that the compounds of the invention of formula I fulfill all requirements of a good prodrug. Specifically, it has been shown that compounds of the invention have up to 10-fold higher solubility over the parent compound at physiological pH. Additionally the compounds of the invention have an unexpected stability in solution at room temperature up to 48 h but also demonstrate a fast hydrolysis in plasma.
- The present invention is a novel compound of formula I, its use as a prodrug in the treatment or prophylaxis of diseases caused by overactivation of respective NMDA receptor subtypes, which include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and diseases such as schizophrenia, anxiety, depression and acute/chronic pain, the use of these compounds for manufacture of corresponding medicaments, processes for the manufacture of these novel compounds and medicaments, containing them.
- The most preferred indication in accordance with the present invention is the treatment or prevention of stroke.
- The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
- As used herein, the term “lower alkyl” denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like.
- Preferred lower alkyl groups are groups with 1-4 carbon atoms.
- The term “five or six member aromatic or non-aromatic heterocyclic ring containing one or more hetero atoms selected from nitrogen, sulfur or oxygen, unsubstituted or substituted by lower alkyl” denotes, for example pyrrol-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl or morpholin-4-yl. Preferred are piperazin-1-yl or morpholin-4-yl. It is preferred that the heterocyclic rings contain one or two hetero atoms.
- The term “physiological pH” means a pH of around 7, preferably about 7.4.
- Exemplary preferred are compounds of formula 1, in which R is —C(O)(CH2)nC(O)OH and n is 2, for example the following compound:
- Succinic acid mono- {(3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl} ester.
-
- and R1 is as above. Especially preferred are compounds wherein R1 is morpholinyl, 4-methyl-piperazinyl or —N(R2)(R3) with R2 and R3 as above.
- Examples of such compounds when R1 is morpholinyl are:
- 4-morpholin-4-ylmethyl-benzoic acid (3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin- 1-yl)-ethanesulfonyl]-phenyl ester; and
- 3-morpholin-4-ylmethyl-benzoic acid (3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester.
-
- R1 is 4-methyl-piperazinyl. Examples of such compounds are:
- 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester,
- 3-(4-methyl-piperazin-1-ylmethyl)-benzoic acid (3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenylester,
-
- R1 is —N(R2)(R3) and R2/R3 are hydrogen or lower alkyl. Examples of such compounds are:
- 4-aminomethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester;
- 3-methylaminomethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester;and
- 4-methylaminomethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester.
- Exemplary preferred are further compounds of formula 1, in which R is —P(O)(OH)2, for example the following compound:
- phosphoric acid mono-{(3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl } ester.
- Also preferred are further compounds of formula 1, in which R is —C(O)(CH2)2NHC(O)(CH2)2NH2, which is 3-(3-amino-propionylamino)-propionic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester.
- The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises
-
-
- wherein m is 1-3 and n is 2-4, or
-
- reacting a compound of formula II with a compound of formula
- HOOC—(CH2)nNHC(O)(CH2)nNH-Boc IV,
-
-
-
-
-
- and
- if desired, converting the compound obtained into a pharmaceutically acceptable acid addition salt.
- In accordance with this procedure, a compound of formula I may be prepared, for example, in accordance with reaction variant a) as follows:
- To a solution of the compound of formula II in a solvent, such as methylene chloride, is added succinic acid or an equivalent compound of formula III and DMAP (dimethylaminopyridine). The reaction mixture is refluxed some hours to obtain the desired compound of formula I-1.
- In accordance with process variant b) a compound, described in example 11, for example phosphoric acid dibenzyl ester (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester is hydrogenated at room temperature in conventional manner to obtain a compound of formula I-2.
- Process variant c) describes the process for preparation of a compound of formula I-3. The process is carried out by reacting the compound of formula II with a compound of formula IV, for example with 3-(3-tert-butoxycarbonylamino-propionylamino)-propionic acid, in the presence of DMAP (4-dimethylaminopyridine) and DAPEC (N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride) at a temperature of about 0° C. The reaction mixture is then treated with TFA (trifluoroacetic acid).
- Furthermore, in accordance with reaction variant d) a compound of formula I-4 is obtained. The reaction is carried out by reaction of the compound of formula II with a compound of formula V, for example with 3-[(tert-butoxycarbonyl-methyl-amino)-methyl]benzoic acid, in the presence of DMAP (4-dimethylaminopyridine) and DAPEC (N-(3-dimethylaminopropyl)-n-ethylcarbodiimide hydrochloride) and subsequently with TFA (trifluoroacetic acid).
- Process variant e) describes the preparation of compounds of formulas I-5 or I-6. A compound of formula VI, for example 4-chloromethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester is treated with morpholine or 4-methyl-piperazin in a solvent, such as methylene chloride.
- The salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids come into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.
- The following schemes 1-3 describe the processes for preparation of the prodrugs of formula I in more detail. The starting compound of formula II (parent compound) may be prepared in accordance with schemes 4 to 6. The compounds, described in these schemes, are known compounds or may be prepared by known methods, for example in accordance with methods, described in WO 00/75109.
- In the schemes the following abbreviations have been used:
- DAPEC N-(3-dimethylaminopropyl)]-n-ethylcarbodiimide hydrochloride
- DMAP 4-dimethylaminopyridine
-
-
-
-
- As mentioned above, the compounds of formula I and their pharmaceutically acceptable addition salts may be used as prodrugs of the parent compounds of formula II, which possess valuable pharmacological properties.
- All of the compounds of the present invention were investigated in accordance with the test given hereinafter. The evidence, that the inventive compounds of formula I may be used as prodrugs of their parent compounds of formula II is shown in accordance with the description given hereinafter.
- The conversion of prodrugs to the corresponding parent compounds is due to a hydrolytic mechanism. There is well known evidence from the literature that similar reactions occur in vivo, hence the decision to study both the stability in plasma and blood was taken.
- Plasma and blood samples from various species were spiked with equimolar amounts (26.7 μM) of the prodrug of the invention and parent drug in DMSO and incubated for different time intervals (up to 120 min) at 37° C. The reaction was stopped by protein precipitation with perchloric acid (0.5 M) followed by centrifugation (5 min. at 15'000 g). This procedure was found to be reliable enough at least when the drug analysis was performed immediately after the incubation.
- The concentrations of formed parent drug in the supernatant was determined by LC-MS: The parent compound together with its hexa-13C-labelled internal standard was enriched on a standard bore trapping column (Lichrospher100, RP18, 5 μm, 4×4 mm, Merck) and separated under isocratic conditions on a narrow-bore analytical column (Symmetry Shield, RP8, 3.5 μm, 2.1×50 mm, Waters) by a mixture of formic acid and methanol as mobile phase. The whole effluent (200 μl/min) of the analytical column was passed to the turbo ion spray interface without splitting. Selected ion monitoring (SIM) in negative mode was used for single quadrupole mass spectrometric detection. The results were expressed as % converted to the parent compound, using the data of the parent drug as 100%-value.
[0040] In the following table the results of the above mentioned test are described. Stability Stability (2 hours) Compound of Solubility Solubility (2 hours) human Example No. (μg/ml at pH 7) (μg/ml at pH 4) rat plasma plasma 1 7689 1800 <10% 10% 2 >37600 594 41% 35% 6 89 8500 7 6706 98% 91% 9 86600 100% 100% 10 26100 100% 100% Compound of 47 7750 (pH 4.8) formula II (parent compound) - The results show that the prodrug approach of the present invention increases the solubility at pH 7.4 (physiological pH) compared with the parent compound (compound of formula II) thereby substantially reducing any precipitation in plasma and local intolerance at the injection site. An increase in solubility at physiological pH has been clearly reached for compound 1 and 2 and to a lesser extent for compound 6. The compounds 7, 9 and 10 were unstable at pH 7.4 over 24 hours, therefore their solubility could only be measured at pH 4.0. These data suggest a higher solubility at pH 7.4 for compounds 9 and 10 than for the parent compound. The solubility of compound 7 at pH 4.0 is similar to the parent compound, but due to the additional charge at pH 7.4 (calculated pKa for the benzylic amine 8.96), a higher solubility can be assumed at this pH.
- The term “stability (2 hours) rat or human plasma” of 100% means that the prodrug of the invention in the plasma has been converted after 2 hours completely into the parent compound. In accordance with the test the inventive compounds of formula I are useful as prodrugs of their parent compounds of formula II.
- The compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
- The compounds of formula I and their pharmaceutically acceptable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
- Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
- Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
- Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
- Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
- Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
- The following Examples 1 to 17 illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.
- The preparation of compounds of formula I, starting with compounds of formula II, is described generically in the description in process variants a) to e) and in schemes 1 to 3. Specifically, the preparation of prodrugs is described in more detail in examples 1 to 10. Examples 11 to 17 describe the preparation of intermediates.
- To a solution of 1.0 g (2.66 mmol) (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol in 25 ml CH2Cl2 were added 320 mg (3.2 mmol) succinic acid and 390 mg (3.2 mmol) dimethylaminopyridine and the reaction mixture was refluxed for 20 hours. The reaction mixture was concentrated to 10 ml and was purified by chromatography over silica gel to give 100 mg (0.21 mmol, 7.4%) succinic acid mono-{(3 S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl}ester as colorless oil.
- MS: m/e=476.2 (M+H+).
- A solution of 1.20 g, (1.73 mmol) phosphoric acid dibenzyl ester (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 40 ml MeOH and 6 ml water was hydrogenated at room temperature (20 bar, 5 h). The reaction mixture was concentrated to 20 ml and 500 ml water were added. The reaction mixture was filtered and the catalyst was washed with water. The filtrate was concentrated under reduced pressure until the product precipitates. The mixture was then cooled to 0° C. and 200 ml MeOH were added dropwise. After two hours the solid was filtered, washed with cold MeOH and dried at 60° C. under high vacuum to give 380 mg (0.83 mmol, 48%) of phosphoric acid mono-{(3S,4 S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl} ester as colorless crystalls.
- MS: m/e=454.4 (M−H)−.
- To a solution of 200 mg (0.38 mmol) 4-chloromethyl-benzoic acid-(3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 10 ml CH2Cl2 were added 53 □1 (0.38 mmol) Et3N and 33 μl (0.38 mmol) morpholine. After 16 hours the reaction mixture was purified by chromatography over silica gel to give 70 mg (0.12 mmol, 32%) 4-morpholin-4-ylmethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester as a colorless solid.
- MS: m/e=579.1 (M+H+).
- Following the general procedure of example 3 the compounds of example 4 to example 6 were prepared.
- The title compound was prepared from 4-chloromethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester and 4-methylpiperazin in 27% yield as a colorless oil.
- MS: m/e=592.2 (M+H+).
- The title compound was prepared from 3-chloromethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester and 4-methylpiperazin, followed by the addition of HCl in 80% yield as a colorless solid.
- MS: m/e592.2 (M+H+).
- The title compound was prepared from 3-chloromethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester and morpholine, followed by the addition of HCl in 18% yield as a colorless solid.
- MS: m/e579.1 (M+H+).
- A solution of 200 mg 4-(tert-butoxycarbonylamino-methyl)-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 3.8 ml TFA was stirred for 1 hour at 0° C. The solvent was removed under reduced pressure and the crude product was diluted in diethylether and 3 drops of a saturated HCl-solution in diethylether were added. Filtration yielded 120 mg (0.22 mmol, 67%) 4-aminomethyl-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester; hydrochloride(1:2) as colorless crystalls.
- MS: m/e=509.4 (M+H+).
- Following the general procedure of example 7 the compounds of example 8 to example 10 were prepared.
- The title compound was prepared from 3-(3-tert-butoxycarbonylamino-propionylamino)-propionic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 13% yield as a colorless solid.
- MS: m/e518.2 (M+H+).
- The title compound was prepared from 3-(3-tert-butoxycarbonyl-methyl-amino-methyl) benzoic acid and (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 93% yield as a colorless solid.
- MS: m/e=523.2 (M+H+).
- The title compound was prepared from 4-(tert-butoxycarbony-methyl-lamino-methyl)-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester in 94% yield as a colorless solid.
- MS: m/e=523.2 (M+H+).
- To a solution of 500 mg (133 mmol) (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol in 20 ml acetonitrile were added 0.64 ml (6.7 mmol) CCl4, 16.3 mg (0.13 mmol) DMAP and 0.48 ml (2.9 mmol) N,N-diisopropylethylamine. The reaction mixture was stirred for 15 min at room temperature and 0.43 ml (1.9 mmol) dibenzylphosphite were added dropwise. After 20 min. 20 ml sat. NaHCO3 solution was added and the aqueous phase was extracted with ethylacetate (3×30 ml) and the combined organic layers were washed with water, dried over MgSO4, filtrated and the solvent was removed under reduced pressure. Purification of the crude product by chromatography over silica gel (ethylacetate/hexane 2/1) yielded 700 mg (11 mmol, 83%) phosphoric acid dibenzyl ester (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester as a colorless solid.
- MS: m/e635.7 (M+H+).
- To a solution of 500 mg (1.33 mmol) (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol in 10 ml methylenechloride were added 368 mg (1.46 mmol) 4-(tert-butoxycarbonylamino-methyl)-benzoic acid, 16.3 mg (0.133 mmol) DMAP and 511 mg (2.66 mmol) N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride and the reaction mixture was stirred at 0° C. After 1 hour, 0.5 N HCl was added and the aqueous layer was extracted with methylenechloride. The combined organic layers were washed with 0.5N HCl solution and brine, dried over NaSO4, filtered and the solvent was removed under reduced pressure to give the crude product.
- Crystallization from diethylether yielded 280 mg (0.460 mmol, 35%) 4-(tert-butoxycarbonylamino-methyl)-benzoic acid (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester as colorless crystalls.
- MS: m/e=609.4 (M+H+).
- Following the general procedure of example 12 the compounds of example 13 to example 15 were prepared.
- The title compound was prepared from (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol and 3-(3-tert-butoxycarbonylamino-propionylamino)-propionic acid in 13% yield as a colorless solid.
- MS: m/e=618.2 (M+H+).
- The title compound was prepared from (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol and 3-[(tert-butoxycarbonyl-methyl-amino)-methyl]-benzoic acid in 70% yield as a colorless gum.
- MS: m/e=623.2 (M+H+).
- The title compound was prepared from (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol and 4-[(tert-butoxycarbonyl-methyl-amino)-methyl]-benzoic acid in 99% yield as a light brown oil.
- MS: m/e=623.2 (M+H+).
- To a solution of 500 mg (1.33 mmol) (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol in 10 ml CH2Cl2 were added 20 mg (0.16 mmol) DMAP and 162 mg (1.60 mmol) Et3N and 302 mg (1.60 mmol) 4-chlormethylbenzoylchloride. After 1 hour water was added and the aequous phase was extracted with methylenechloride (3×20 ml). The combined organic layers were dried over MgSO4, filtered and the solvent was removed under reduced pressure. The crude product was purified by chromatography over silica gel to give 280 mg (0.53 mmol, 40 %) 4-chloromethyl-benzoic acid 4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenyl ester as colorless foam.
- MS: m/e=528.2 (M).
- Following the general procedure of example 16 the compound of example 17 was prepared.
- The title compound was prepared from (3S,4S)-4-[2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethanesulfonyl]-phenol and 3-chlormethylbenzoylchloride in 80% yield as a colorless solid.
- MS: m/e=528.1 (M).
- Tablets of the following composition are manufactured in the usual manner:
mg/tablet Prodrug 5 Lactose 45 Corn starch 15 Microcrystalline cellulose 34 Magnesium stearate 1 Tablet weight 100 - Capsules of the following composition are manufactured:
mg/capsule Prodrug 10 Lactose 155 Corn starch 30 Talc 5 Capsule fill weight 200 - The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelatine capsules.
- Suppositories of the following composition are manufactured:
mg/supp. Prodrug 15 Suppository mass 1285 Total 1300 - The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository molds of suitable size, left to cool, the suppositories are then removed from the molds and packed individually in wax paper or metal foil.
Claims (18)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00117918 | 2000-08-21 | ||
EP00117918.3 | 2000-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020040037A1 true US20020040037A1 (en) | 2002-04-04 |
US6407235B1 US6407235B1 (en) | 2002-06-18 |
Family
ID=8169594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/931,431 Expired - Lifetime US6407235B1 (en) | 2000-08-21 | 2001-08-16 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
Country Status (36)
Country | Link |
---|---|
US (1) | US6407235B1 (en) |
EP (1) | EP1313703B1 (en) |
JP (1) | JP4162991B2 (en) |
KR (1) | KR100589991B1 (en) |
CN (1) | CN1227230C (en) |
AR (1) | AR030373A1 (en) |
AT (1) | ATE386022T1 (en) |
AU (2) | AU2001285894B2 (en) |
BR (1) | BR0113348A (en) |
CA (1) | CA2419279C (en) |
CY (1) | CY1107937T1 (en) |
CZ (1) | CZ303319B6 (en) |
DE (1) | DE60132782T2 (en) |
DK (1) | DK1313703T3 (en) |
EC (1) | ECSP034489A (en) |
EG (1) | EG24293A (en) |
ES (1) | ES2299508T3 (en) |
HK (1) | HK1059083A1 (en) |
HR (1) | HRP20030125B1 (en) |
HU (1) | HU229802B1 (en) |
IL (1) | IL154254A0 (en) |
JO (1) | JO2289B1 (en) |
MA (1) | MA26947A1 (en) |
MX (1) | MXPA03001311A (en) |
MY (1) | MY136065A (en) |
NO (1) | NO324941B1 (en) |
NZ (1) | NZ523990A (en) |
PA (1) | PA8525601A1 (en) |
PE (1) | PE20020291A1 (en) |
PL (1) | PL204215B1 (en) |
PT (1) | PT1313703E (en) |
RS (1) | RS51467B (en) |
RU (1) | RU2272027C2 (en) |
SI (1) | SI1313703T1 (en) |
WO (1) | WO2002016321A1 (en) |
ZA (1) | ZA200300894B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02009311A (en) * | 2000-03-21 | 2003-03-12 | Procter & Gamble | HETEROCYCLIC SIDE CHAIN CONTAINING, Nminus;SUBSTITUTED METALLOPROTEASE INHIBITORS. |
US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
WO2007072179A2 (en) * | 2005-12-19 | 2007-06-28 | Methylgene, Inc. | Histone deacetylase inhibitors for enhancing activity of antifungal agents |
US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
MX2009006542A (en) | 2006-12-19 | 2009-06-30 | Methylgene Inc | Inhibitors of histone deacetylase and prodrugs thereof. |
SI3066091T1 (en) | 2013-11-05 | 2019-09-30 | Astrazeneca Ab | Nmda antagonist prodrugs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4410822A1 (en) | 1994-03-24 | 1995-09-28 | Schering Ag | New piperidine derivatives |
TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
-
2001
- 2001-08-16 PA PA20018525601A patent/PA8525601A1/en unknown
- 2001-08-16 US US09/931,431 patent/US6407235B1/en not_active Expired - Lifetime
- 2001-08-16 PE PE2001000820A patent/PE20020291A1/en not_active Application Discontinuation
- 2001-08-17 MY MYPI20013876A patent/MY136065A/en unknown
- 2001-08-17 AR ARP010103939A patent/AR030373A1/en active IP Right Grant
- 2001-08-19 JO JO2001136A patent/JO2289B1/en active
- 2001-08-20 KR KR1020037002485A patent/KR100589991B1/en not_active IP Right Cessation
- 2001-08-20 SI SI200130812T patent/SI1313703T1/en unknown
- 2001-08-20 AU AU2001285894A patent/AU2001285894B2/en not_active Ceased
- 2001-08-20 PT PT01965201T patent/PT1313703E/en unknown
- 2001-08-20 EP EP01965201A patent/EP1313703B1/en not_active Expired - Lifetime
- 2001-08-20 CN CNB01814361XA patent/CN1227230C/en not_active Expired - Fee Related
- 2001-08-20 WO PCT/EP2001/009561 patent/WO2002016321A1/en active IP Right Grant
- 2001-08-20 IL IL15425401A patent/IL154254A0/en not_active IP Right Cessation
- 2001-08-20 RS YUP-130/03A patent/RS51467B/en unknown
- 2001-08-20 EG EG20010906A patent/EG24293A/en active
- 2001-08-20 NZ NZ523990A patent/NZ523990A/en not_active IP Right Cessation
- 2001-08-20 BR BR0113348-9A patent/BR0113348A/en not_active Application Discontinuation
- 2001-08-20 AU AU8589401A patent/AU8589401A/en active Pending
- 2001-08-20 RU RU2003107572/04A patent/RU2272027C2/en not_active IP Right Cessation
- 2001-08-20 AT AT01965201T patent/ATE386022T1/en active
- 2001-08-20 CZ CZ20030492A patent/CZ303319B6/en not_active IP Right Cessation
- 2001-08-20 DK DK01965201T patent/DK1313703T3/en active
- 2001-08-20 DE DE60132782T patent/DE60132782T2/en not_active Expired - Lifetime
- 2001-08-20 PL PL361387A patent/PL204215B1/en unknown
- 2001-08-20 CA CA002419279A patent/CA2419279C/en not_active Expired - Fee Related
- 2001-08-20 ES ES01965201T patent/ES2299508T3/en not_active Expired - Lifetime
- 2001-08-20 HU HU0301548A patent/HU229802B1/en not_active IP Right Cessation
- 2001-08-20 JP JP2002521197A patent/JP4162991B2/en not_active Expired - Fee Related
- 2001-08-20 MX MXPA03001311A patent/MXPA03001311A/en active IP Right Grant
-
2003
- 2003-01-31 ZA ZA200300894A patent/ZA200300894B/en unknown
- 2003-02-19 NO NO20030781A patent/NO324941B1/en not_active IP Right Cessation
- 2003-02-20 HR HR20030125A patent/HRP20030125B1/en not_active IP Right Cessation
- 2003-02-20 EC EC2003004489A patent/ECSP034489A/en unknown
- 2003-02-21 MA MA27052A patent/MA26947A1/en unknown
-
2004
- 2004-03-16 HK HK04101906A patent/HK1059083A1/en not_active IP Right Cessation
-
2008
- 2008-05-08 CY CY20081100485T patent/CY1107937T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3302351B2 (en) | 4-Aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridine having neurotrophic and neuroprotective activity | |
NZ232542A (en) | N-phenyl-n-(4-piperidinyl)amide derivatives; preparatory processes and pharmaceutical compositions | |
PT92628B (en) | METHOD FOR THE PREPARATION OF N-SUBSTITUTED AZA-HETEROCYCLIC CARBOXYLIC ACID AND PHARMACEUTICAL COMPOSITIONS THAT CONTAINS THEM | |
US6677330B1 (en) | Fluorides of 4-substituted piperidine derivatives | |
PT94070A (en) | PROCESS FOR THE PREPARATION OF PIPERAZINE DERIVATIVES | |
US6407235B1 (en) | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | |
US5053521A (en) | Various n-substituted 3-piperidine carboxylic acids or n-substituted 3-pyridinecarboxylic acids and derivatives thereof | |
US8487104B2 (en) | KAT II inhibitors | |
AU2001285894A1 (en) | Prodrugs to NMDA receptor ligands | |
US20070185168A1 (en) | Piperidine derivatives | |
US5071858A (en) | Antipsychotic benzothiopyranylamines | |
EP0329169A1 (en) | N-(lower alkyl)-2-(3'-ureidobenzyl)-pyrrolidines | |
WO1995025100A1 (en) | Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists | |
EP0663395A1 (en) | 3-(phenylalkylaminoalkyloxy)-5-phenylpyrazole derivatives, process and intermediates for their preparation and their use as cardiac rhythm reduction agent | |
US4010161A (en) | Piperazinoethyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3Δ-pyrazolin-4-yl)carbamates | |
EP0508004A1 (en) | Phenylsulfonylalkanoic acid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F.HOFFMANN-LA ROCHE AG;REEL/FRAME:012466/0821 Effective date: 20010920 |
|
AS | Assignment |
Owner name: F.HOFFMANN-LA ROCHE AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALANINE, ALEXANDER;BUETTELMANN, BERND;FISCHER, HOLGER;AND OTHERS;REEL/FRAME:012504/0342 Effective date: 20010906 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: EVOTEC INTERNATIONAL GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOFFMANN-LA ROCHE INC.;REEL/FRAME:030530/0684 Effective date: 20130603 |
|
FPAY | Fee payment |
Year of fee payment: 12 |